Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Pivotal Phase III Study of RHB-104 for the Treatment of Pulmonary Nontuberculous Mycobacteria (NTM) Infections

Trial Profile

A Pivotal Phase III Study of RHB-104 for the Treatment of Pulmonary Nontuberculous Mycobacteria (NTM) Infections

Planning
Phase of Trial: Phase III

Latest Information Update: 13 Aug 2018

At a glance

  • Drugs Clarithromycin/clofazimine/rifabutin (Primary)
  • Indications Mycobacterial infections
  • Focus Registrational; Therapeutic Use
  • Sponsors RedHill Biopharma
  • Most Recent Events

    • 13 Aug 2018 Planned initiation date changed from 1 Jul 2018 to 1 Jan 2019, according to a RedHill Biopharma media release.
    • 13 Aug 2018 According to a RedHill Biopharma media release, the trial is expected to be initiated in first quarter of 2019.
    • 09 Apr 2018 According to a RedHill Biopharma media release, this study is expected to be initiated in H2/2018, subject to completion of a supportive non-clinical program and additional input from the FDA.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top